Resource impact summary report
Resource impact summary report
This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'population and treatments', 'unit costs', 'capacity' and 'payscales' worksheets in the template to reflect local data and assumptions.
Guidance recommendations
See NICE's recommendations on sotatercept for treating pulmonary arterial hypertension.
Financial and capacity resource impact
The key driver of resource impact is the difference in price between sotatercept and alternative treatments.
The company has a commercial arrangement. This makes sotatercept available to the NHS at a discount.
Users can input the confidential price of sotatercept and amend other variables in the resource impact template.
The payment mechanism for the technology is determined by the responsible commissioner and depends on whether the technology is classified as high cost.
Table 1 shows the impact on capacity activity in each of the next 3 years.
| Year | Number of outpatient appointments | Number of blood tests (Hgb and platelet count) |
|---|---|---|
|
Current practice (without sotatercept) |
2,300 |
0 |
|
Year 1 |
4,200 |
1,900 |
|
Year 2 |
3,400 |
3,000 |
|
Year 3 |
2,700 |
3,400 |
Capacity impact is greatest in year 1 because there are more outpatient appointments in year 1 of treatment and year 1 has the largest increase in people having sotatercept (an increase in users from 0% to 50% of the eligible population).
For further analysis or to calculate the financial and capacity impact, see the resource impact template.
Eligible population for sotatercept
People with pulmonary arterial hypertension with a World Health Organization functional class (WHO FC) 2 or 3 and a low-intermediate European Society of Cardiology risk rating, are eligible to start treatment with sotatercept.
Table 2 shows the population who are eligible for sotatercept and the number of people who are expected to have sotatercept in each of the next 3 years, excluding forecast population growth.
| Eligible population and uptake | Number of people eligible for sotatercept | Uptake for sotatercept (%) | Number of people starting treatment each year (if applicable) | Number of people continuing treatment from previous years (if applicable) | Number of people having sotatercept each year |
|---|---|---|---|---|---|
|
Current practice without sotatercept |
760 |
0 |
0 |
0 |
0 |
|
Year 1 |
760 |
50 |
380 |
0 |
380 |
|
Year 2 |
760 |
80 |
230 |
380 |
610 |
|
Year 3 |
760 |
90 |
80 |
600 |
680 |
The uptake for sotatercept is based on an internal NICE assumption that uptake will increase rapidly to a maximum of 90%, it is assumed that no treatment ever reaches 100% uptake.
Treatment options for the eligible population
The comparator treatment for the eligible population is selexipag. It is an oral tablet which is self-administered.
For more information about the treatments, such as dose and average treatment duration, see the resource impact template.
Key information
| Time from publication to routine commissioning funding |
90 days |
|---|---|
| Programme budgeting category |
PBC 10X Problems of circulation |
| Commissioner |
NHS England |
| Provider |
NHS hospital trusts |
| Pathway position |
Second line |
About this resource impact summary report
This resource impact summary report accompanies the NICE technology appraisal guidance on sotatercept for treating pulmonary arterial hypertension and should be read with it.
ISBN: 978-1-4731-9550-9
This page was last updated: